•  
  •  
  •  
  •  

2026-05-24 10:23:02

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Prithvi Exchange India Ltd announces financial performance for the 4th quarter ended March 31, 2026
  • SMS Pharmaceuticals Reports Robust FY26 Performance: PAT Soars 48% and EBITDA Margins Expand to 19%
  • NBCC India Ltd secures 2 orders worth Rs. 42.55 crores
  • Icon Facilitators Limited receives order worth Rs. 2.69 crore
  • Fabtech Technologies Cleanrooms Ltd receives order worth Rs. 65.10 crores

Keywords Selected:  EIR

Stock Report

  • Supriya Lifescience Receives USFDA EIR with VAI Classification for Maharashtra API Facility
  • Zydus receives EIR for oncology injectable manufacturing facility in SEZ1, Ahmedabad
  • Granules India's Packaging Facility in US gets FDA EIR with No Action Indicated Status
  • Lupin Receives EIR from US FDA for its Goa Facility
  • Biocon Ltd receives EIR from USFDA with VAI status for Cranbury facility
  • Lupin receives EIR from US FDA for its Nagpur Injectable Facility
  • Granules Life Sciences Pvt Ltd facility receives EIR from USFDA
  • Indoco receives EIR from the USFDA for its API manufacturing facility at Patalganga
  • Zydus receives EIR for the injectable facility located at Jarod
  • Lupin Receives EIR from U.S. FDA for its Aurangabad (CSN) Facility
  • Zydus receives EIR for the oncology injectable manufacturing facility in SEZ1, Ahmedabad
  • Alembic Pharmaceuticals Ltd receives EIR from USFDA for facility at Panelav
  • SMS Pharmaceuticals Ltd receives EIR from USFDA for Central Laboratory Analytical Services
  • Unichem Laboratories Ltd receives EIR from USFDA classifying Roha API facility as VAI
  • SMS Lifesciences India Ltd receives EIR with VAI status from USFDA for API facility at Kazipally
  • EIR from USFDA, for Shilpa Medicare Ltd. Unit VI, Bengaluru.
  • Neuland Laboratories Ltd receives EIR from USFDA for Unit 2 at Pashamylaram Village
  • Concord Biotech Limited receives EIR from USFDA for API facility at Dholka
  • Alembic Pharmaceuticals Ltd receives EIR from USFDA for API-III facility at Karakhadi
  • Zydus receives EIR for the API manufacturing facility at Ankleshwar
  • Zydus receives EIR for the API manufacturing facility at Dabhasa
  • Zydus receives EIR for the Ambernath API manufacturing facility
  • India Glycols Limited receives EIR from USFDA for Dehradun Plant
  • USFDA classifies Emcure Pharmaceuticals Ltd's API facility at Kurkumbh as VAI

Latest Post

  • Prithvi Exchange India Ltd announces financial performance for the 4th quarter ended March 31, 2026
  • SMS Pharmaceuticals Reports Robust FY26 Performance: PAT Soars 48% and EBITDA Margins Expand to 19%
  • NBCC India Ltd secures 2 orders worth Rs. 42.55 crores
  • Icon Facilitators Limited receives order worth Rs. 2.69 crore
  • Fabtech Technologies Cleanrooms Ltd receives order worth Rs. 65.10 crores


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025